Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Current Liabilities (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Total Current Liabilities for 13 consecutive years, with $138.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 13.09% to $138.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $138.4 million, a 13.09% increase, with the full-year FY2025 number at $138.4 million, up 13.09% from a year prior.
  • Total Current Liabilities was $138.4 million for Q4 2025 at Iovance Biotherapeutics, up from $125.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $138.4 million in Q4 2025 to a low of $83.2 million in Q1 2024.
  • A 3-year average of $109.9 million and a median of $116.3 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: decreased 4.65% in 2024, then surged 47.44% in 2025.
  • Iovance Biotherapeutics' Total Current Liabilities stood at $110.3 million in 2023, then increased by 10.91% to $122.3 million in 2024, then increased by 13.09% to $138.4 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Total Current Liabilities are $138.4 million (Q4 2025), $125.8 million (Q3 2025), and $129.2 million (Q2 2025).